Most secondary sale guides treat a sale as a single event: you decide on a price, sign documents, funds arrive. But a meaningful number of sellers — employees and early investors at well-known private companies — are sitting on equity across multiple issuers, or across multiple grant dates within the same company. For those sellers, every individual transaction is also a decision about all the transactions that follow.
This article is for that seller. We focus on the decisions that compound: holding period management, lot selection across tranches, QSBS qualification layering, and the interaction between secondary sale proceeds and other income in the same tax year.
Holding period: the most durable lever you control
Long-term capital gains treatment requires holding an asset for more than one year before sale. For shares issued through an 83(b) election, the holding period begins at grant — assuming the election was filed within 30 days. For shares received through option exercise, the holding period generally begins at exercise. This distinction compounds over time: a seller who exercised options in tranches across multiple years may have shares with materially different holding periods sitting in what feels like a single position.
When you sell in the secondary market, the lot you transfer determines the tax character of the gain. If you transfer shares from a January 2025 exercise in June 2026, you are selling long-term. If you transfer shares from a March 2026 exercise in June 2026, you are selling short-term — and short-term gains are taxed as ordinary income, potentially at rates well above the long-term capital gains rate.
The practical implication: before initiating any secondary sale, map your lots. Know the specific acquisition date, cost basis, and character (ISO vs. NSO, restricted stock vs. common acquired through exercise) of every block of shares you might transfer. The decision of which lot to sell is often worth more in after-tax proceeds than a meaningful improvement in the gross price.
Lot selection when you have multiple tranches
Suppose you have three tranches of shares in the same company: 10,000 shares exercised in 2021 at $0.50, 8,000 shares exercised in 2023 at $2.00, and 5,000 shares exercised in 2025 at $8.00. Today's secondary price is $20.00. All three lots produce a gain at that price, but the gain per share and the tax character differ substantially.
The 2021 tranche has the highest gain per share and is clearly long-term. The 2025 tranche has the lowest gain per share and, depending on your exercise date, may still be short-term. The obvious instinct — sell the high-gain lot first to maximize gross proceeds — can backfire if it eliminates shares that might qualify for QSBS treatment, or if it pushes you into a higher income bracket in the current year.
There is no universal answer, but there are concrete questions: Does either lot qualify for QSBS? Is selling the highest-gain lot this year going to push net investment income above the 3.8% surtax threshold? Is there a planned liquidity event or IPO in the next 12–18 months that would alter the calculus entirely? Each question changes which lot to sell and when.
QSBS stacking: when multiple issuers are in play
Section 1202 of the Internal Revenue Code allows non-corporate taxpayers to exclude up to $10 million (or 10× the adjusted basis, whichever is greater) of gain per issuer on the sale of qualified small business stock. The per-issuer cap is significant: a seller holding shares in two or three qualifying companies can potentially exclude up to $10 million of gain per company.
QSBS status is not guaranteed and depends on conditions at the time of issuance — the company must have been a domestic C-corporation with aggregate gross assets under $50 million when shares were issued, among other requirements. Many late-stage secondary sellers find that their earlier tranches qualify while later tranches, issued after the company's gross assets exceeded the threshold, do not.
For the repeat seller, sequencing matters. If you hold QSBS-eligible shares in two companies and non-QSBS shares in a third, and you anticipate one of the QSBS companies approaching a liquidity event, there may be a case for selling the non-QSBS position in the secondary market first — recognizing taxable gain now — and preserving the QSBS shares for the event that triggers the full exclusion. The ordering of sales across companies is a planning decision, not an administrative one.
Income smoothing and the bracket problem
Secondary sale proceeds are taxable in the year of settlement. A seller who realizes $800,000 of long-term capital gain in a single year may cross the $553,850 married-filing-jointly threshold that triggers the 20% federal long-term capital gains rate (2026 figures; confirm current thresholds with a tax advisor). The same $800,000 recognized over two calendar years might remain entirely in the 15% bracket.
Splitting a sale across a year-end — selling half of your intended position before December 31 and the remainder in January — is a straightforward mechanism for income smoothing. Secondary marketplaces with predictable settlement timelines make this feasible: a transaction initiated in mid-December that settles within five business days lands in the current tax year; a transaction initiated on December 28 that settles in January falls into the next year. Settlement date, not trade date, determines when gain is generally recognized.
Understanding a marketplace's settlement timeline before you plan a year-end sale is therefore not merely a convenience question — it is a tax planning input.
ISO AMT exposure in a year with secondary sales
Sellers who exercised ISOs and are holding shares may face alternative minimum tax (AMT) complexity if they also transact in the secondary market in the same year. The ISO spread at exercise is an AMT preference item even if no gain has been realized for regular tax purposes. When you sell ISO shares in the same calendar year as exercise, the position can convert to an NSO-equivalent for tax purposes — the spread becomes ordinary income, not AMT preference. But if the exercise was in a prior year, you may carry an AMT credit that offsets regular tax in years when your regular tax exceeds your AMT.
A year in which you realize significant secondary sale proceeds — pushing regular tax higher — can be an opportunity to absorb prior-year AMT credits. This is not a reason to time a sale purely around AMT credits, but it is a factor worth quantifying with a tax advisor before you finalize your sale calendar.
Keeping records across multiple sales
The administrative burden of multi-sale tax planning is real. Specific identification of lots requires that you designate the exact shares sold at or before the time of sale and that you receive written confirmation from your broker or transfer agent. For SPV-routed secondary sales, the SPV manager typically issues a K-1 at year end; the underlying cost basis and character of the shares flow through to members based on their proportionate interest.
- Maintain a running lot schedule: date acquired, number of shares, cost basis per share, acquisition type (grant, exercise, purchase), and QSBS eligibility assessment.
- Document the specific lot designation in writing at the time of each sale — email confirmation to your marketplace or transfer agent is generally sufficient.
- Track the issuer's 409A history if you exercised at multiple dates; the 409A value at exercise may affect your AMT basis in ISO shares.
- Retain SPV operating agreements and K-1s from prior-year sales — basis carryforward calculations depend on them.
- Confirm settlement dates in writing; the gap between trade date and settlement date can move gain recognition across tax years.
If you are ready to map your position against current secondary demand, visit the Limen Markets seller intake page. If you want to model your net proceeds before engaging, the net proceeds modeling guide covers the full calculation from gross price to after-tax cash.